TRDA Company Profile and Key Details

Entrada Therapeutics, Inc. (NASDAQ:TRDA) closed at $11.68 USD, losing -$0.25 (-2.10%) from the previous close of $11.93. The stock is currently mid-range between its 52-week high and low $4.93 and $12.93. With a market capitalization of about $446.40 million, Entrada Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.12). Key stats such as the average daily volume over the past year has been around 207.78 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Entrada Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dipal Doshi, the company employs approximately 183 people and listed since October 29, 2021. Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.

TRDA has shown sold momentum, gaining 6.73% over the past week and 80.92% over the past quarter, though year-to-date performance is up 3.31%. Short-term trend indicators are bearishly aligned (SMA20 13.87%, SMA50 17.11%, SMA200 60.44%). The stock’s 14-day RSI is 69.92 (firm momentum), while the ATR of 0.76 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 2.24% below its high and over 159.43% above its low. Average 10-day trading volume of 211.36 thousand shares is in line with the 3-month average of 205.77 thousand, indicating normal recent market interest.

Entrada Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $7.21. This means the shares are trading above this model’s fair value.

The latest quarter delivered EPS of -$1.06. The next quarter is forecast at -$1.15. Next year's EPS is expected at -$1,806.17. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $20.00. The high target offers 71.23% upside. The low target suggests 71.23% downside. The mean target is $20.00. This offers 71.23% upside. Entrada Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -1.44%. The prior quarter beat by 20.93%. Over the last six quarters, Apple has recorded several small beats. These include 138.46% in August 13, 2024.

Entrada Therapeutics, Inc. has 38.04 million shares outstanding. The public float is 19.08 million shares, elevated short interest at 5.24% of float. This equals 1.08 million shares. The short ratio is 4.28 days. Institutional investors hold 89.31% of the float. Insiders own 12.24%. MPM BIOVENTURES 2018, L.P. holds 4.38 million shares, MPM BioVentures 2014, L.P. has 4.38 million shares and 5AM Ventures V, L.P. has 2.96 million shares. Over the past six months, insider transactions show net buying. They sold 408.91 thousand shares across 3 transactions.